The company exhibits structural inefficiency with a TTM gross margin of -1.87% and an operating margin of -312,016.95%, reflecting costs that far exceed its nominal $6,202 TTM revenue.
| Sales/Revenue | 34.55K | 6.2K | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 28.92K | 6.32K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 101.87% | - | - | - | - |
| Gross Profit | 5.63K | -116 | 0 | 0 | 0 | 0 |
| Gross Margin % | 16.3% | -1.87% | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 5.45M | 19.35M | 3.09M | 1.34M | 976.35K | 25.48K |
| OpEx % of Revenue | - | 312015.08% | - | - | - | - |
| Selling, General & Admin | 4.49M | 18.43M | 3.09M | 1.34M | 976.35K | 27.79K |
| SG&A % of Revenue | - | 297118.04% | - | - | - | - |
| Research & Development | 957.54K | 923.91K | 144.36K | 72.05K | 175.32K | 0 |
| R&D % of Revenue | - | 14897.03% | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -144.36K | -72.05K | -175.32K | -2.32K |
| Operating Income | -5.44M | -19.35M | -3.09M | -1.34M | -976.35K | -25.48K |
| Operating Margin % | -15745.85% | -312016.95% | - | - | - | - |
| Operating Income Growth % | - | -526.52% | -130.5% | -37.25% | -3731.81% | - |
| EBITDA | -4.07M | -19.35M | -11.65M | 0 | 3.34M | 2.31K |
| EBITDA Margin % | -11787.82% | -312016.95% | - | - | - | - |
| EBITDA Growth % | 83.91% | -66.16% | - | -100% | 144436.48% | - |
| D&A (Non-Cash Add-back) | 2.02M | 0 | 0 | 1.34M | 0 | 27.79K |
| EBIT | -5.32M | -19.35M | -11.65M | 4.47M | 3.34M | 0 |
| Net Interest Income | -9.83M | -8.53M | -342.95K | 5.8M | 4.32M | 0 |
| Interest Income | 5.01K | 0 | 548.68K | 5.81M | 4.32M | 0 |
| Interest Expense | 9.84M | 8.53M | -892K | 8.97K | 0 | 0 |
| Other Income/Expense | -6.32M | -5.13M | -9.45M | 5.8M | 4.32M | 5 |
| Pretax Income | -11.76M | -24.48M | -12.54M | 4.46M | 3.34M | -25.48K |
| Pretax Margin % | -34039.68% | -394725.06% | - | - | - | - |
| Income Tax | 0 | 0 | 1.01K | 0 | 626 | 0 |
| Effective Tax Rate % | 0% | 0% | -0.01% | 0% | 0.02% | 0% |
| Net Income | -11.76M | -24.48M | -12.54M | 4.46M | 3.34M | -25.48K |
| Net Margin % | -34039.68% | -394725.06% | - | - | - | - |
| Net Income Growth % | 54.78% | -95.27% | -380.85% | 33.65% | 13210.89% | - |
| Net Income (Continuing) | -11.76M | -24.48M | -12.54M | 4.46M | 3.34M | -25.48K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7.87 | -16.38 | -18.17 | 9.31 | 3.72 | -0.04 |
| EPS Growth % | 73.23% | 9.85% | -295.17% | 150.27% | 10073.19% | - |
| EPS (Basic) | - | -16.38 | -18.17 | 9.31 | 3.72 | -0.04 |
| Diluted Shares Outstanding | 1.49M | 1.49M | 689.91K | 479.48K | 898.44K | 682.81K |
| Basic Shares Outstanding | 1.49M | 1.49M | 689.91K | 479.48K | 898.44K | 682.81K |
| Dividend Payout Ratio | - | - | - | - | - | - |
Imminent insolvency and dilution
According to the latest financial disclosures, ASBP generated a nominal TTM revenue of $6,202, which underscores the company's pre-commercial status and highlights the absence of any recurring clinical volume or established market presence within the highly competitive molecular diagnostic sector in which the firm currently operates.
The sporadic nature of the reported revenue suggests that these figures are likely derived from non-recurring pilot projects or research grants rather than a scalable diagnostic business model. Investors should monitor whether the company can transition from these transactional inflows to a sustainable, high-margin service revenue stream.
As reported in recent income statements, ASBP's gross margin has fluctuated significantly, reaching a negative -1.87% on a TTM basis, which indicates that the direct costs of laboratory operations currently exceed the minimal revenue generated, reflecting a total lack of economies of scale in its current configuration.
The inability to maintain positive gross margins suggests that the company's current laboratory-developed test model is not yet optimized for commercial viability. Without a shift toward automated, high-volume platforms, the firm will likely continue to struggle with structural cost burdens that prevent any meaningful path to profitability.
Based on the provided quarterly data, ASBP's operating expenses, particularly SG&A and R&D, have consistently dwarfed its negligible revenue, resulting in an operating margin of -312,016.95% and confirming that the current cost structure is entirely unsustainable for a company with such limited capital and market traction.
The heavy reliance on R&D and administrative overhead to maintain a public entity status appears to be consuming the company's limited liquidity at an alarming rate. Management's expense discipline remains questionable, as the firm has failed to align its operational burn with any tangible progress toward commercialization.
Financial filings indicate that ASBP holds only $1M in cash reserves, a figure that appears dangerously insufficient given the company's historical quarterly burn rates, suggesting that the firm faces an imminent risk of insolvency or the necessity for highly dilutive emergency financing to continue its operations.
Short-sellers would likely focus on the widening gap between the company's cash position and its persistent operating losses, which leaves little room for error in clinical development. The lack of a clear pathway to insurance reimbursement further complicates the investment thesis, as the company's survival remains tethered to capital markets.
Quick answers to the most common questions about buying ASBP stock.
For fiscal year 2025, Aspire Biopharma Holdings, Inc. (ASBP) reported total revenue of $0.0M.
Aspire Biopharma Holdings, Inc. (ASBP) reported a net loss of $24.5M for the fiscal year ending 2025.
Aspire Biopharma Holdings, Inc. (ASBP) reported an operating income of $-19.4M, resulting in an operating profit margin of -312016.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Aspire Biopharma Holdings, Inc. (ASBP) generated $-0.0M in gross profit for the year, representing a gross profit margin of -1.9%. This demonstrates the company's core pricing power and production efficiency.